| Abstract |
[Abstract] Objective: To study the application value of escitalopram combined with electroconvulsive shock treatment in diabetic patients with depression and its influence on negative mood and psychology. Methods: A total of 130 patients with diabetes and depression treated in our hospital from June 2021 to June 2022 were selected for observation. Patients were divided into observation group and control group by random number table method, with 65 patients in each group. Both groups were routinely treated with hypoglycemic drugs such as insulin, acarbose and metformin, the control group was given escitalopram on this basis, the observation group on the basis of the control group were treated for 2 months with electroconvulsive shock treatment, and then the two groups of Hamiltons anxiety / depression scale(HAMA / HAMD) score before and 2 months after treatment, self-rating of anxiety / depression (SAS / SDS) score, and the two groups of adverse effects were compared. Results: The overall response rate of the observation group was 98.46% (64 / 65), which was significantly higher than 86.15% (56 / 65) of the control group, and the difference was statistically significant (P <0.05). The HAMA, HAMD scores, SAS and SDS scores were lower than before treatment, and the observation group was significantly lower than the control group respectively,the difference was statistically significant (P <0.05). The overall incidence of adverse effects in the observation group was 9.23% (6 / 65), compared with 6.15% (4 / 65) in the control group,had not significant (P> 0.05). Conclusion: Escitalopram and electroconvulsive shock have good application value in patients with diabetes and depression, and can also regulate the negative mood and psychology of patients, with high safety and worth promoting.
|